BIO4 is a viable bone matrix containing endogenous bone forming cells and is intended to facilitate bone repair and regeneration. It aims at providing a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities.
“With the introduction of BIO4, Stryker now plays in the growing $199M Cellular Allograft Market,” said Spencer Stiles, president of Stryker Spine.
More articles on devices:
Synergy Disc Replacement names GM Medical Pacific exclusive distributor — 5 things to know
7 key trends in the China orthopedic device market
Innovating beyond implants — DePuy Synthes launches data-collection software & patient video
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
